---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-048961"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2021-09-27T23:59:59+00:00"
generated_at: "2026-06-29T01:24:55.178865+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sarepta to initiate pivotal Part B of MOMENTUM study for SRP-5051 in DMD patients

## Summary
- Positive FDA interactions enable early start of Part B of MOMENTUM study for SRP-5051.
- Part B expected to serve as pivotal study seeking accelerated approval for exon 51 skipping DMD patients.
- Study will enroll 20-40 patients, ages 7-21, both ambulatory and non-ambulatory.
- Company anticipates initiating Part B in Q4 2021; protocol submission next week.
- SRP-5051 is a next-generation PPMO therapy; prior Part A data suggested efficacy.

## SEC filing metadata
- accession: 0001564590-21-048961
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2021-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000156459021048961/0001564590-21-048961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000156459021048961/srpt-8k_20210927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-048961
- JSON: https://secwatch.observer/filing/0001564590-21-048961.json
- Plain text: https://secwatch.observer/filing/0001564590-21-048961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.